
<ns0:uwmetadata xmlns:ns0="http://phaidra.univie.ac.at/XML/metadata/V1.0" xmlns:ns1="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0" xmlns:ns10="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0" xmlns:ns11="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0/entity" xmlns:ns12="http://phaidra.univie.ac.at/XML/metadata/digitalbook/V1.0" xmlns:ns13="http://phaidra.univie.ac.at/XML/metadata/etheses/V1.0" xmlns:ns2="http://phaidra.univie.ac.at/XML/metadata/extended/V1.0" xmlns:ns3="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/entity" xmlns:ns4="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/requirement" xmlns:ns5="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/educational" xmlns:ns6="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/annotation" xmlns:ns7="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/classification" xmlns:ns8="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/organization" xmlns:ns9="http://phaidra.univie.ac.at/XML/metadata/histkult/V1.0">
  <ns1:general>
    <ns1:identifier>o:3029</ns1:identifier>
    <ns1:title language="en">Rivaroxaban versus dabigatran: a new era in venous thromboembolism treatment</ns1:title>
    <ns1:language>en</ns1:language>
    <ns1:description language="en">SUMMARY: Considering the frequency of deep vein thrombosis and pulmonary embolism, the therapy of these two conditions takes an important place in
vascular surgery. Among numerous therapeutic options, new oral anticoagulants, such as rivaroxaban or dabigatran, represent a great improvement in the treatment of venous thromboembolism. Searching MEDLINE base until December 1, 2015 using MESH term “Rivaroxaban versus Dabigatran in VTE”, we found 7 studies investigating the usage of new oral anticoagulants in venous thromboembolism treatment. The total of 18,841 patients was enrolled. No head–to–head studies were found. Benefits such as lower therapy price, oral use and greater comfort for patients and health providers place new oral anticoagulants to the frontline of venous thromboembolism treatment. However, we need head to-head studies to have a clear picture of these two drugs.</ns1:description>
    <ns1:description language="sr">SAŽETAK:
Uzimajući u obzir incidenciju tromboze dubokih vena i plućne embolije, terapija ovih stanja zauzima značajno mesto u vaskularnoj hirurgiji. Postoji
više izbora lečenja, a novi oralni antikoagulansi, kao što su rivaroksaban i dabigatran, predstavljaju veliki pomak u terapiji venskih tromboembolijskih
stanja.
Pretražujući bazu podataka MEDLINE koristeći MESH izraz “Rivaroxaban versus Dabigatran in VTE” pronađeno je 7 studija sa ukupno 18841 ispitanikom. Nije pronađena nijedna studija koja direktno upoređuje upotrebu rivaroksabana i dabigatrana u terapiji venskih tromboembolijskih stanja.
Oralna upotreba, niža cena lečenja kao i veći komfor za pacijente i lekare prednosti su novih oralnih antikoagulanasa u terapiji venskih tromboembolijskih stanja.
Studije koje direktno uporedjuju Rivaroxaban i Dabigatran su neophodne radi boljeg razumevanja efekata ova dva leka.</ns1:description>
    <ns1:keyword language="en">Key words: Rivaroxaban, Dabigatran, new oral anticoagulants, venous thromboembolism, deep vein thrombosis, pulmonary embolism</ns1:keyword>
    <ns1:keyword language="sr">Ključne reči: Rivaroksaban, Dabigatran, novi oralni antikoagulansi, venski tromboembolizam, dubinska venska tromboza, embolija pluća</ns1:keyword>
    <ns2:identifiers>
      <ns2:resource>91552100</ns2:resource>
      <ns2:identifier>126220809</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>1552101</ns2:resource>
      <ns2:identifier>0301-0619</ns2:identifier>
    </ns2:identifiers>
  </ns1:general>
  <ns1:lifecycle>
    <ns1:upload_date>2023-10-17T11:04:49.490Z</ns1:upload_date>
    <ns1:status>44</ns1:status>
    <ns2:peer_reviewed>yes</ns2:peer_reviewed>
    <ns1:contribute seq="0">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname>Đorđe</ns3:firstname>
        <ns3:lastname>Radak</ns3:lastname>    
    <ns3:conor>12465767</ns3:conor>
        <ns3:orcid>0000-0003-3199-5613</ns3:orcid>
      </ns1:entity>
      <ns1:date>2016</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="1">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname>Nenad</ns3:firstname>
        <ns3:lastname>Đukić</ns3:lastname>
        <ns3:conor>29990247</ns3:conor>
      </ns1:entity>
      <ns1:date>2016</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="2">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname>Mihailo</ns3:firstname>
        <ns3:lastname>Nešković</ns3:lastname>
        <ns3:conor>29988455</ns3:conor>
        <ns3:orcid>0000-0003-4829-985X</ns3:orcid>
      </ns1:entity>
      <ns1:date>2016</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="3">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname>Srđan</ns3:firstname>
        <ns3:lastname>Babić</ns3:lastname>
        <ns3:conor>19073383</ns3:conor>
        <ns3:orcid>0000-0001-9659-9190</ns3:orcid>
      </ns1:entity>
      <ns1:date>2016</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="4">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname>Slobodan</ns3:firstname>
        <ns3:lastname>Tanasković</ns3:lastname>
        <ns3:conor>19201127</ns3:conor>
        <ns3:orcid>0000-0003-4216-6693</ns3:orcid>
      </ns1:entity>
      <ns1:date>2016</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="5">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname>Petar</ns3:firstname>
        <ns3:lastname>Popov</ns3:lastname>
        <ns3:conor>12532071</ns3:conor>
        <ns3:orcid>0009-0002-6337-3755</ns3:orcid>
      </ns1:entity>
      <ns1:date>2016</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="6">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname>Predrag</ns3:firstname>
        <ns3:lastname>Gajin</ns3:lastname>
        <ns3:conor>19182183</ns3:conor>
        <ns3:orcid>0000-0001-9707-8805</ns3:orcid>
      </ns1:entity>
      <ns1:date>2016</ns1:date>
    </ns1:contribute>
  </ns1:lifecycle>
  <ns1:technical>
    <ns1:format>application/pdf</ns1:format>
    <ns1:size>105769</ns1:size>
    <ns1:location>https://unilib.phaidrabg.rs/o:3029</ns1:location>
  </ns1:technical>
  <ns1:rights>
    <ns1:cost>no</ns1:cost>
    <ns1:copyright>yes</ns1:copyright>
    <ns1:license>16</ns1:license>
    <ns1:description language="sr">https://scindeks.ceon.rs/JournalDetails.aspx?issn=0301-0619</ns1:description>
  </ns1:rights>
  <ns1:classification>
    <ns1:purpose>70</ns1:purpose>
    <ns7:keyword language="en" seq="0">616.14-005.6:615.22</ns7:keyword>
  </ns1:classification>
  <ns1:organization>
    <ns8:hoschtyp>92000001</ns8:hoschtyp>
    <ns8:orgassignment>
      <ns8:faculty>71A11</ns8:faculty>
    </ns8:orgassignment>
  </ns1:organization>
  <ns12:digitalbook>
    <ns12:name_magazine language="sr">Medicinska istraživanja</ns12:name_magazine>
    <ns12:volume>50</ns12:volume>
    <ns12:booklet>1</ns12:booklet>
    <ns12:from_page>14</ns12:from_page>
    <ns12:to_page>18</ns12:to_page>
    <ns12:releaseyear>2016</ns12:releaseyear>
  </ns12:digitalbook>
</ns0:uwmetadata>
